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Abstract
Chronic inflammation has long been associated with a wide range of malignancies, is now widely
accepted as a risk factor for development of cancer, and has been implicated as a promoter of a
variety of cancers including hematopoietic malignancies. We have described a mouse model
uniquely suited to examine the link between inflammation and lymphoma in which the Tax
oncogene, expressed in activated T and NK cells, perpetuates chronic inflammation that begins as
microscopic intraepithelial lesions and develops into inflammatory nodules, subcutaneous tumors,
and large granular lymphocytic leukemia. The use of bioluminescent imaging in these mice has
expanded our ability to interrogate aspects of inflammation and tumorigenesis non-invasively. Here
we demonstrate that bioluminescence induction in these mice correlated with inflammation
resulting from wounding, T cell activation, and exposure to chemical agents. In experiments in
which long-term effects of inflammation on disease outcome were monitored, the development of
lymphoma was promoted by an inflammatory stimulus. Finally we demonstrated that activation of
T-cells in T-cell receptor (TCR) transgenic TAX-LUC animals dramatically exacerbated the
development of subcutaneous TCR- CD16+ LGL tumors. The role of activated T-cells and acquired
immunity in inflammation-associated cancers is broadly applicable to hematopoietic malignancies,
and we propose these mice will be of use in dissecting mechanisms by which activated T-cells
promote lymphomagenesis in vivo.

Background
Malignant transformation of the cancer cell is promoted
and often preceded by changes in the tumor microenvironment, rich in inflammatory cells, growth factors, and
DNA damage promoting agents. A wide range of malig-

nancies are promoted by chronic inflammation associated
with chemical, physical, or microbial factors [1-4]. The
diversity of oncogenic factors associated with inflammation highlights the importance of characterizing those
common to a wide range of malignancies. The cellular
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effectors, signaling pathways, and secreted regulators
involved in chronic inflammation are the soil in which
the seeds of these cancers are initiated.
T-cells are central regulators of the immune response; Tcells are recruited to sites of chronic inflammation, and
the infiltration of T-cells within the tumor is a critical
determinant of neoplastic outcome. Naïve CD4+ T-cells,
or T-helper cells, that have not previously encountered an
antigen differentiate into one of four committed lineages
(TH1, TH2, TH17, Treg) in response to antigen presenting
cells [5-10]. Conventionally, TH1 and TH2 cells promote
the elimination of intracellular and extracellular pathogens respectively. More recently TH17 cells have been
characterized for their ability to promote inflammation by
recruiting neutrophils to peripheral tissues to remove
extracellular pathogens, while Treg cells repress inflammation to keep immune hyperactivity in check. While there
is no question that T-cells are recruited to sites of chronic
inflammation, it is unclear whether activated T-cells promote or restrict malignancies in vivo.
Molecular pathways often involved in inflammationassociated tumorigenesis include JNK, STAT3, HIF-1, and
nuclear factor κB (NFκB) signaling, and generation of
reactive oxygen species [1,3,11,12]. These pathways are
interrelated and signaling through NFκB serves as a master
regulator. NFκB signaling during tumorigenesis prevents
apoptosis and promotes proliferation, metastasis, and
angiogenesis [13]. NFκB is activated in T-lymphocytes
after T-cell receptor (TCR) engagement, as well as in other
cell types through activation of toll-like receptors (TLR)
[11,14,15]. NFkB is over-expressed in a wide range of
malignancies, particularly cancers refractory to chemotherapy [16,17].
Soluble mediators of migration, proliferation, and signaling pathways of cells in the tumor microenvironment
include cytokines and chemokines. The balance of
cytokines produced in a tumor regulates the type and
extent of inflammatory infiltrate, the level of cytotoxicity
and genetic instability, the degree of neovascularization,
and the innate and adaptive immune responses to the
tumor [14,16,17].
We have developed and characterized a triple transgenic
mouse model of inflammation-associated cancer that
allows us to experimentally activate T cells and NFkB signaling pathways prior to the onset of tumorigenesis and
to non-invasively monitor inflammation and tumor progression using bioluminescent imaging (BLI). The first
transgene expresses the human T-cell leukemia virus type
1 (HTLV-1) Tax oncogene under the granzyme B promoter
(GZB), which restricts expression to activated T- and NKcells [18,19]. In activated T- and NK- cells of these mice,
Tax constitutively activates both the canonical and non-
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canonical pathways of NFkB [20]. Moreover, tumors that
arise in GZB-TAX mice are composed of malignant
CD16hi large granular lymphocytes (LGLs), infiltrating
CD16lo neutrophils, and CD16- T- and B- lymphocytes
[18,20-25]. Moreover, Tax stimulates and recruits inflammatory cells through induction of IFN-gamma, IL-1, IL-6,
GM-CSF, RANK ligand, and TNFα [21,24,26].
The second transgene expresses firefly luciferase (LUC)
under the regulation of the HTLV-1 LTR. When mice carry
both the LTR-LUC and GZB TAX transgenes (TAX-LUC
mice), the events associated with the expression of Tax,
including T-cell activation, constitutive NFKB activation,
and spontaneous tumorigenesis, can be monitored noninvasively by BLI. In these mice, inflammation was closely
correlated with lymphomagenesis, and sensitive imaging
technology enabled us, for the first time, to identify all
stages in spontaneous tumor development including primary microscopic lesions, pre-malignant inflammatory
nodules, localized tumors, and disseminated disease [25].
Thus in TAX-LUC mice, Tax expressed in mature lymphocytes activates luciferase expression which is detected
non-invasively using D-luciferin as a substrate for BLI.
Moreover, we recently described the use of luminol to
monitor neutrophil myeloperoxidase activity, using the
same imaging modality, as an independent reporter for
tumor associated inflammation [27].
The third transgene is a genetic manipulation of the T-cell
receptor that restricts its recognition to ovalbumin such
that activation of T- cells in TCR transgenic mice can be
experimentally induced by administration of ovalbumin.
The majority of circulating T- cells are activated in TCROVA transgenic animals upon administration of ovalbumin [6,7]. The combination of these three transgenes and
the properties of the oncoprotein Tax, gave us the ability
to activate T cells, stimulate NFkB pathways, promote
inflammation, and image these processes non-invasively
using luciferase mediated BLI. We used this model to
determine whether activated T- cells promote or suppress
tumorigenesis in vivo. We discovered that the activation of
T- cells in triple transgenic mice dramatically exacerbated
tumor development and the onset and dissemination of
LGL lymphoma. We propose that these findings are applicable to many forms of hematologic malignancy especially those associated with constitutive activation of
NFkB and chronic inflammation. We further propose that
this animal model will be a broadly useful tool in the
delineation of the mechanisms by which T-cells promote
tumorigenesis in vivo.

Methods
Transgenic Mice
Individual strains of transgenic mice utilized in this report
have been previously described. In LTR-LUC, the 0.7 Kb
XhoI-HindIII 5'LTR fragment of pHTE-1 drives firefly luciPage 2 of 10
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ferase (pGL-3; Promega) [25]. In GZB-TAX, HTLV-1 Tax is
regulated by the 5' flanking region (-1170 to +36) of the
human granzyme B gene [18]. Mice were housed under
pathogen free conditions and animal protocols were
approved by the Animal Studies Committee in accordance
with the guidelines of the Washington University School
of Medicine.
Flow Cytometry
Cell suspensions derived from organs or tumors were
stained with FITC-conjugated FcγR II/III antibodies (clone
2.4G2; BD Pharmingen) for 30 minutes at 4°C and analyzed on a FACScan (Becton Dickinson). In three color
experiments, cells were incubated with unlabelled FcγR II/
III antibodies for 30 minutes to block free surface FcγR,
and counterstained with PE-conjugated antibodies
against TCRova (clone KJ1-26; eBioscience) and PE-Cy5
conjugated anti-CD4 (cloneGK1.5 eBioscience).
Imaging
The IVIS100 system (Xenogen) was used to image bioluminescence in anesthetized mice (isoflurane inhalation).
Standard imaging parameters included D-luciferin dose
15 mg i.p; luminol dose 200 mg/kg i.v; exposure 300 sec;
binning 4; f/stop 1; no optical filter. When luminol and
D-luciferin images were obtained from the same animal,
the first substrate was allowed to clear for 24 hours prior
to injection with the second. When necessary, hair was
removed by shaving or depiliation prior to imaging. Color
scale unless otherwise indicated is ×104 photons/sec/cm2/
sr. The indicated agents were injected ip at the following
dosages: con A, 2.5 mg/kg; LPS, 2.5 mg/kg; CFA, 100 μl in
100 μl PBS; poly(I:C), 1 mg/kg. For experiments involving
BrdU, animals were injected with 1 mg BrdU, i.p. (BD
Pharmingen) 24 hours prior to necropsy.
Histology
Histology was performed as described [25]. Briefly, tissues
were fixed in 4% paraformaldehyde and embedded in
paraffin for serial sectioning. The primary BrdU antibody
(Dako clone Bu20a) was used at a dilution of 1:150. The
biotinylated primary antibody was incubated for 1 hour
and labeled streptavidin applied for 30 minutes. Slides
were developed with DAB chromogen then counterstained in Richard Allen hematoxylin. Sections were visualized with a Nikon Eclipse E400 microscope and digital
images were obtained using a Magnafire camera and software (Optronics).

Results
Imaging Inflammation and Tumorigenesis in vivo
TAX-LUC mice are doubly transgenic mice in which i) the
Tax gene from HTLV-1 is restricted to activated NK and T
cells by the granzyme B promoter and ii) luciferase, under
the control of the HTLV-1 LTR, is activated by Tax [25]. In
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principle, luciferase, which catalyzes a light emitting reaction in the presence of its substrate D-luciferin, serves as
an indirect biomarker for activated NK and T cells in TAXLUC mice. Alternatively, upon activation of leukocytes
during inflammation, neutrophil myeloperoxidases are
expressed that catalyze the production of hypochlorous
acid from hydrogen peroxide and chloride ions [27].
Luminol emits light when exposed to oxidizing agents
and can be used to sensitively and non-invasively detect
leukocyte activity during inflammation in vivo. We have
shown that administration of either luminol or D-luciferin produces bioluminescence in primary TAX-LUC
tumors and that microscopic bioluminescent lesions precede tumorigenesis. We sought to determine the effects of
inflammation on bioluminescence and tumorigenesis in
this model.
We first asked whether wounding was sufficient to result
in a luciferase-mediated bioluminescent signature in TAXLUC mice. We found that minor incisions on the ear, tail
or foot (Fig. 1) were sufficient to produce a significant bioluminescent signature and that introduction of adjuvant
in the wound increased the intensity and duration of the
signal. These data confirmed a close correlation between
wounding and reporter expression in vivo.
Generalized T Cell Activation is Associated with
Tumorigenesis
While Tax is activated in malignant LGL cells of inflamed
tumors, the granzyme B promoter is also inducible in T
and NK cells by T-cell receptor (TCR)-dependent, TCRindependent, and cytokine-mediated stimuli [28]. A
number of direct and indirect inducers of generalized T
cell activation were utilized to locally activate this promoter and image Tax activity during inflammation. These
included phorbol 12-myristyl 13-acetate (PMA), which
when administered topically, promotes T lymphocyte
infiltration and activation mediated by protein kinase C,
and has been shown to stimulate the human granzyme B
promoter in transgenic mice [29,30]. Topical administration of PMA to the ear resulted in luciferase based bioluminescence in TAX-LUC mice, but not LTR-LUC mice (Fig.
2A, top panels) even though a massive inflammatory infiltrate was seen in all PMA treated ears (Fig. 2B). Luminol
based bioluminescence emanating from the PMA treated
ears compared to the vehicle treated contralateral ears
(Fig. 2A, bottom panels) served as a reporter for inflammation. The intensity of luminol BLI after PMA treatment
was greater in TAX-LUC mice than LTR-LUC littermates
that lack the Tax transgene (fold flux increase 11.5 vs. 7.4;
p = 0.018). These findings serve as proof of principle for
the appropriate regulation of the transgenes in TAX-LUC
mice, confirm that acute inflammation is sufficient to produce bioluminescence in this model, and suggest that Tax
expression exacerbates the inflammatory response in vivo.
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Figure 1induced bioluminescence in TAX-LUC mice
Wound
Wound induced bioluminescence in TAX-LUC mice.
Surgical lesions were experimentally introduced in ear (A)
limb (B), and tail tissue (C). The effect of adjuvant on wound
associated bioluminescence was also examined (B, C). Treatments include 1) vehicle, 2) CFA, 3) wound, and 4) wound
and CFA. Images were obtained 0.5 hrs before treatment,
and 0.5, 2, 24, and 48 hrs after treatment. Representative
images shown from A) 30 minutes, B) 2 hours, and C) 24 and
48 hours after treatment.
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Figure 2myristyl
Phorbol
transgenic
mice acetate stimulation of bioluminescence in
Phorbol myristyl acetate stimulation of bioluminescence in transgenic mice. For each mouse, the left ear
was treated with PMA and the right ear with vehicle. A) Representative images obtained 2 hours after treatment are
shown for two LTR-LUC mice (left panels) and two TAXLUC mice (right panels) comparing bioluminescence following administration of D-luciferin (top panels) and Luminol
(bottom panel). B) Histology showing edema and inflammatory infiltrate associated with topical application of PMA (48
hours; Bar = 1 mm). C) Aggressive lymphoma in TAX-LUC
mice from intravenous administration of con A. D) Histology
is H/E stained sections of bioluminescent tumors in the cervical lymph nodes and small intestine of a con A treated TAXLUC mouse.
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Con A, a potent lectin with broad activity towards T lymphocytes, is also known to activate the granzyme B promoter. To determine whether induction of inflammation
affected tumorigenesis in this model, we examined 5 TAXLUC mice and 5 LTR-LUC in each group given tail vein
injections of con A or saline (Fig. 2C). While TAX-LUC
mice develop peripheral tumors most frequently on the
tail, this method of con A inoculation is known to preferentially target T cell activation in the liver [31,32]. All 5
con A treated mice developed liver bioluminescence, and
two died within 1 week of acute hepatitis. The other 3 con
A treated mice developed lymphoma initiated in the liver
with spread to the gastrointestinal tract, spleen, and cervical nodes, as detected by BLI and histological analysis at
necropsy (Fig. 2C). While the 5 saline injected TAX-LUC
mice developed tail tumors, none developed a similar
form of aggressive lymphoma, characterized by massive
visceral infiltration. LTR-LUC animals did not develop
tumors. This experiment suggested that con A-induced
inflammation and T cell activation in TAX-LUC mice were
sufficient to modify the presentation of lymphoma from
peripheral and indolent to visceral and aggressive.
We also utilized CFA a mixture of paraffin oil, surfactant,
and heat-killed mycobacteria that leads to TH1 lymphocyte activation [33]. In addition, we examined inducers of T cell activation through effects on TLRs on antigenpresenting cells (APCs). These inducers included poly I:C,
a mimic of double stranded RNA that activates the interferon response, and LPS, found in the cell wall of gram
negative bacteria, that rapidly activates pyrogenic
cytokines and cells involved in innate immunity [34]. In
the tumors that arise in TAX-LUC animals, the malignant
cells are rarely T cells, but instead are CD16Hi LGLs that
lack TCRs. Primary TAX-LUC tumors also contain a large
population of CD16Lo cells which are predominantly neutrophils and CD16- cells which include tumor infiltrating
T cells. We next sought to determine if bioluminescence
resulting from acute inflammation correlates with the
recruitment or proliferation of CD16Hi LGLs. The representative results of intraperitoneal injections into 3 mice
each of saline, con A, CFA, poly I:C, and LPS are shown in
Fig. 3. Mice were imaged 0.5 hour prior to injections and
then at 2 and 6 hours after injection, then sacrificed and
examined. BLI performed prior to injection exhibited very
low background levels of activity primarily within the gastrointestinal tract TAX-LUC mice. Con A treatment
resulted in increased numbers of CD16lo cells and BrdU+
cells in the spleen and liver compared to saline treated
animals (Fig. 3A, B), whereas the number of CD16Hi cells
increased in spleen but not liver. After con A injection BLI
was increased in the gastrointestinal tract and liver as
compared to saline injected animals (Fig. 3C). Intraperitoneal injection of CFA was similar to the effects of con A.
The number of BrdU positive cells in the spleen and liver
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was increased after CFA treatment, and infiltrates of lymphoid cells in the liver were apparent. Two hours after
CFA injection, bioluminescence localized primarily to the
liver (Fig. 3C). Intraperitoneal injection of poly(I:C) and
LPS also resulted in increased numbers of CD16lo cells
and BrdU+ cells in spleen and liver compared to animals
injected with saline. Unlike Con A and CFA, bioluminescence in TAX-LUC mice after treatment with poly(I:C) and
LPS was more evident in the spleen and gastrointestinal
tract than liver.
Taken together, these studies indicated that bioluminescence in TAX-LUC mice serves as a sensitive indicator of
acute inflammation in vivo. However, the bioluminescence profile does not correlate with CD16Hi cells nor proliferating cells, suggesting the light emitting cells during
inflammation are not identical to the population of cells
that subsequently undergo malignant transformation.
While malignant LGLs in TAX-LUC tumors are bioluminescent, these results demonstrated that during acute
inflammation other luciferase-expressing cell types predominate, possibly activated T cells. Based on these findings, we sought to use a genetic approach to determine if
activated T cells promote tumorigenesis in TAX-LUC mice.
Specific T-Cell Receptor Activation Accelerates TaxMediated Tumorigenesis
DO11.10 mice carry a transgenic MHC class II restricted
rearranged T cell receptor which reacts with a specific ovalbumin (OA) peptide antigen [6,7]. IP administration of
OA results in deletion of immature CD4+ CD8+ TCRlo thymocytes and expansion of CD4+ TCRHi thymocytes.
Within 3 days post injection all of the immature non-OVA
reactive thymocytes are removed and OA reactive CD4+ T
cells represent approximately 70% of T cells in these mice.
In order to examine the specific effects of TCR activation,
triple transgenic mice were utilized, resulting from breeding TAX-LUC mice with DO mice (Fig. 4). In one experiment, 5 TAX-LUC-DO mice were inoculated with OA in
CFA, and 2 control TAX-LUC-DO mice were inoculated
with CFA alone. Double transgenic LUC-DO and TAXLUC mice were also inoculated with OA in CFA to serve as
controls. The immune response to OA in CFA could be
observed non-invasively in these mice using BLI (Fig. 4AB) which served as an internal control to ensure each
immunization produced a response. Bioluminescence
was detectable 7 hours after injection and by day 3 predominantly localized to the spleen (Fig. 4A). Subsequent
injections in primed animals produced a bioluminescent
response of increased intensity and duration (Fig. 4B).
Interestingly, bioluminescence was also detected in LUCDO animals, although it was more intense in Tax transgenic animals (Fig. 4C). These results demonstrate that
OA in CFA is sufficient to activate basal HTLV LTR transcriptional activity, which is further activated by induction
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Bioluminescence
Figure 3
in TAX-LUC mice correlates with inflammatory response
Bioluminescence in TAX-LUC mice correlates with inflammatory response. Representative data are shown from
groups of 3 mice each inoculated intraperitoneally with saline, con A, CFA, poly (I:C), or LPS. A) FACS histograms for CD16lo
cells (red curve) and CD16hi cells (black curve) in liver and spleen 6 hrs after treatment. B) Representative BrdU IHC results
from the spleen and liver. C) Bioluminescent images obtained 2 hrs after treatment. Bar = 1 mm.
of Tax expression in TAX-LUC-DO mice. Over the course
of 1 year, 4-10 tail tumors arose in each of the TAX-LUCDO mice inoculated with OA in CFA, and 2-3 tail tumors
arose in each of the TAX-LUC mice (Fig. 4C, numbers at
bottom of panels). No tumors arose in mice lacking the
Tax transgene (LUC-DO), nor in the two TAX-LUC-DO
controls that received no OA.
These findings were confirmed and extended in additional experiments (Fig. 5A). Significantly more tumors
were noted in triple transgenic TAX-LUC-DO mice inocu-

lated with OA in CFA compared to those inoculated with
CFA alone (6.5 vs 3.1, p = 0.0014) (Fig. 5A, panel 1).
Moreover, survival was significantly shorter in TAX-LUCDO and TAX-DO mice treated with OA in CFA compared
to those administered CFA alone (Fig. 5B). No tumors
developed in the absence of the Tax transgene in LUC-DO
mice, DO mice, or LUC mice (Fig. 5A, panels 2, 3, and 4,
respectively). Doubly transgenic TAX-LUC mice lacking
the specific TCR had fewer tumors in the presence than
absence of OA (1.5 vs. 4.3 p = 0.0083). Since the average
tumor onset in Tax mice occurs within 200-300 days and
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Figure 4
Bioluminescence
imaging of T-cell receptor activation in TAX-LUC-DO mice
Bioluminescence imaging of T-cell receptor activation in TAX-LUC-DO mice. Image (A) and quantitation (B) of the
bioluminescence time-course following injections, indicated by arrows in B. C) BL images taken 1 hour prior to and 7 hours
after immunization. All animals were injected with CFA and OA except where indicated. The total tail tumors in each animal
during the course of the experiment is enumerated at the bottom of the figure.

many animals do not develop tumors until the second
year of life, some Tax positive animals did not develop
tumors during the time course of this experiment [18].
While the OA-restricted TCR in TAX-LUC-DO animals is
expressed on CD4+ lymphocytes, the presence of TCRova
cells in tumors was variable. Typically, the malignant LGL
population in tumors that spontaneously arise in TAXLUC mice is TCR-, and tumor infiltrating lymphocytes are
TCR+. This is consistent with what we observed in tumors
arising on the tails in TAX-LUC-DO mice which included
both TCR- and TCR+ cells (Fig. 5C). In contrast, tumors
arising in the gastrointestinal (GI) tract, which were only

found in TAX-LUC-DO animals treated with OA, were
composed of TCR+ cells with a minor population of cells
expressing exceptionally high levels of TCRova (Fig. 5C).
Alternatively, tumors arising in the ears contained very
few TCR+ cells and were primarily composed of malignant
LGLs. Representative histology (Fig. 5D) for tumors arising in OA stimulated TAX-LUC-DO mice, includes examples of tumors invading spleen, lung, and liver as well as
primary tumors arising in intestine and peripheral tissues.
In each case, a proliferation of lymphoid cells is evident,
however, the size, morphology, and expression profiles of
CD16 and TCRova indicated that tumors arising in the gut
were distinct from peripheral tumors that typically arise
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Figurereceptor
T-cell
5
activation stimulates tumorigenesis in TAX-LUC-DO mice
T-cell receptor activation stimulates tumorigenesis in TAX-LUC-DO mice. A) Total number of tumors indicated by
a single circle for each animal, with closed circles indicating mice immunized with CFA + OA and open circles indicating mice
immunized with CFA alone. Red bars indicate the average number of tumors for each group. B) Survival curve for TAX-LUCDO mice immunized with CFA and OA or CFA alone. C) FACS histograms of TCR expression in tumors that arose on the tail,
small intestine, or ear of treated triple transgenics. D) Histology of tumors that infiltrated the spleen, lung, and liver as well as
a comparison of gut and tail tumors. E) TCRova, CD16, and TAX expression in tail and gut tumors from a TAX-LUC-DO
mouse.
on TAX-LUC mice. Unlike peripheral tumors arising in the
tail or ear, gut tumors include very few if any CD16
expressing cells but an abundance of TCRova + and Tax
expressing cells (Fig. 5E). Taken together, these results
indicate that T cell activation in TCR transgenic TAX-LUC
mice resulted in increased peripheral tumor burden,
decreased survival, and the presentation of a novel form
of visceral lymphoma composed of CD16- TCRova lymphocytes similar to tumors that arose in con A treated
TAX-LUC mice.

Discussion
Cells within an inflammatory microenvironment are
capable of promoting malignancy. The cell types involved
in this process, and the mechanisms by which it occurs
have not been fully characterized. While T cells are

recruited to sites of chronic inflammation and are present
in many tumors, they have been shown to have varied
roles in the regulation of cancer. CD8+ cells may play a
role in restricting neoplasms through direct cellular cytotoxicity or release of cytokines or chemokines [35].
CD4+CD25+ Treg cells repress inflammation, but have
been found to be elevated in several different human cancers, and suppress immune responses [5]. CD4+ TH17
cells, that secrete IL-17, have been shown to accumulate in
the tumor microenvironment and contribute to the
pathogenesis of cancers [8]. Which of these competing
activities dominates the microenvironment of a chronically inflamed tumor in vivo? We sought to determine if
activated T- cells repress or promote tumor growth in a
mouse model of inflammation associated cancer. For
these studies, we have used several different forms of gen-
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eral or specific T- lymphocyte activation and in our experimental model we found that activated T- cells in the
context of inflammation strongly favor a tumor promoting environment. In the animal model we used, Tax transgenic tumors are characterized by constitutive NF-kB
activity, expression of IL-1, IL6, TNF-α, and GM-CSF,
severe neutrophilia, and marked osteolytic activity, all of
which are also associated with TH17 activity
[20,21,24,26]. IL-1 and IL-6 produced by tumor cells,
fibroblasts, and APCs are potent in expanding memory
TH17 cells [9]. IL-17 promotes expansion and recruitment
of neutrophils and cooperates with TLR ligands to
enhance inflammatory reactions [10]. While IL-17 is not
expressed by the malignant LGL cells that arise in TAXLUC tumors, it is elevated in the serum of tumor-bearing
mice. The role of TH17 cells in promotion of early events
in inflammation-associated tumorigenesis in this model
will be the focus of future studies.
The following model is consistent with information available to date. Tumorigenesis in TAX-LUC mice begins as a
microscopic intraepithelial lesions associated with activated neutrophils, detected with luminol, and oncogene
expression, measured by luciferase activity. Among the
inflammatory cells attracted to sites of wounds, neutrophils arise first, followed by mast cells and monocytes,
which differentiate into macrophages. It is of interest that
wounding has previously been found to be critical for
tumorigenesis in v-jun transgenic mice [36]. The next step
in tumorigenesis in this model results from the ability of
Tax to directly and indirectly mediate constitutive activation of both the canonical and non-canonical pathways of
NFkB. This prevents apoptosis and promotes proliferation
of Tax expressing LGL cells that have been recruited to the
wound [13]. The third step in our model is genetic instability also catalyzed by Tax. Both NFkB activity and
genetic instability are associated with cancers unrelated to
HTLV-1 disease. In our model Tax is simply a mechanism
to accomplish these activities in an accelerated manner in
vivo. The fourth step in TAX-LUC tumor development, the
focus of this work, is the activation of T- cells that have
also been recruited to the wound. Activated T-cells release
cytokines and chemokines, promote induction of angiogenesis, and regulate the immune response via direct cell
contact and activation of macrophages, dendritic cells,
and neutrophils. The resulting cytokine storm exerts systemic effects with a broad range of biological consequences. Neutrophil infiltration into Tax transgenic
tumors is prominent, and is often accompanied by
peripheral blood neutrophilia [18,26]. Neutrophils may
promote tumor cell proliferation directly. Alternatively,
myeloid-derived suppressor cells have been described
which inhibit anti-tumor immunity [37]. It is noteworthy
that adjuvant-induced inflammation alone was not sufficient to promote tumorigenesis in TAX-LUC or TAX-LUC-
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DO mice. The addition of OVA to stimulate the T-cells was
required for the phenotype, indicating a critical role for Tcells in this step. This model of tumorigenesis for inflammation associated cancers is consistent with the data currently available and leaves open many avenues of further
inquiry.
Although alternative Tax transgenic models have been
described, only two other models were characterized by
enhanced T- cell proliferation [38-40]. The role of inflammation in those model systems remains to be assessed.
We are currently developing new transgenic lines to pursue these lines of inquiry including TAX-LUC mice in
which i) Tax activity can be experimentally regulated in an
inducible expression system, ii) NFkB signaling is
restricted, or iii) cytokines critical for development or activation of T- or NK- cells are absent. We propose that the
answers to these questions will have broad implications
to cancers associated with similar mechanisms of origin.

Conclusions
Bioluminescent imaging with HTLV-1 Tax transgenic mice
provided a sensitive marker of inflammation and tumor
formation. Use of this model demonstrated that wounding, T- cell activation, and exposure to chemical agents
exacerbated development of lymphoma.
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